Company intelligence / Profile preview

SoftOx Defense Solutions AS

Fornebu, Akershus, Norwaysoft-ox.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company is developing antimicrobial solutions with clinical trials ongoing. Their inhalation solution (SIS) has shown efficacy against respiratory pathogens including severe pathogens/biological weapons, and they are planning a Phase 1b trial in Galway, Ireland[5].

Therapeutic areas: Infectious Diseases
Modalities: Antimicrobial solutions
Industry: Biotech

Drug pipeline

2 assets

SoftOx Inhalation Solution

Phase 2

Indications: Ventilator-Associated Pneumonia, Respiratory infections

1 more asset in the full pipeline.

Request access →

Partnerships

European Defence Fund (EDF)/COUNTERACT project

Beyond the preview

Go deeper on SoftOx Defense Solutions AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SoftOx Defense Solutions AS.

Explore the full profile